Structure Therapeutics (GPCR) Net Cash Flow (2022 - 2026)

Structure Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$483.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 2680.55% year-over-year to -$483.5 million; the TTM figure through Mar 2026 stood at $164.0 million (up 202.16% YoY), while the FY2025 annual figure was $630.1 million, up 1486.47% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$483.5 million, down from $696.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $696.7 million in Q4 2025, with the low at -$483.5 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$5.1 million (2025), against an average of $12.4 million.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 26692.02% in 2025, then plunged 2680.55% in 2026.
• Structure Therapeutics' Net Cash Flow stood at -$2.0 million in 2022, then jumped by 4055.82% to $79.2 million in 2023, then tumbled by 103.31% to -$2.6 million in 2024, then surged by 26692.02% to $696.7 million in 2025, then plunged by 169.39% to -$483.5 million in 2026.
• Business Quant data shows GPCR's Net Cash Flow at -$483.5 million in Q1 2026, $696.7 million in Q4 2025, and -$44.1 million in Q3 2025.